文献速递肿瘤 PET/CT核素与放射性配体治疗

根治性前列腺切除术后早期生化复发前列腺癌中68Ga-PSMA配体PET/CT预检阳性率的预测模型验证

Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model.
PubMed 文献 · EJNMMI Res · 2020-02-03

本研究回顾性纳入292例根治性前列腺切除术后早期生化复发且PSA 0.2-1 ng/ml的患者,验证两种预测模型对68Ga-PSMA-11配体PET/CT阳性的预测能力。结果显示预测概率与实际阳性发现高度一致,但列线图本身预测准确性欠佳,需谨慎使用;因研究设计为内部验证,模型外推性可能受限。

要点

  • 在PSA 0.2-0.5 ng/ml亚组中,紧凑模型预测阳性概率57%,综合模型59%,实际阳性率59%(89/151)。
  • 在PSA >0.5-1 ng/ml亚组中,紧凑模型预测阳性概率72%,综合模型74%,实际阳性率79%(112/141)。
  • 预测模型AUC紧凑模型0.71(95%CI 0.65-0.78),综合模型0.74(95%CI 0.68-0.80),预测准确性欠佳。

核心结论

  • 外部验证显示计算出的预检概率与实际68Ga-PSMA-11配体PET/CT发现高度一致,证实预测模型能判断68Ga-PSMA-11配体PET是否存在阳性病灶。
  • 然而,列线图本身的预测准确性欠佳,应谨慎使用。
  • 此外,由于研究设计为内部验证,模型的外推性可能受限。
  • 鉴于医疗资源有限及混合影像技术成本,预测模型可能有助于患者选择。

研究设计与样本

  • 回顾性纳入2016年1月至2017年6月期间接受68Ga-PSMA-11配体PET/CT的292例根治性前列腺切除术后早期生化复发且PSA 0.2-1 ng/ml的连续患者。
  • 队列分为极低PSA值亚组(0.2-0.5 ng/ml,n=151)和低PSA值亚组(>0.5-1 ng/ml,n=141)。
  • 根据先前发表的综合预测模型(使用PSA值、ISUP分级组、T和N分期、是否接受雄激素剥夺治疗(ADT)、既往放疗)和紧凑模型(仅使用PSA值、ADT和分级组)计算每例患者的预检阳性概率。
  • 由一名经验丰富的核医学医师分析所有68Ga-PSMA-11配体PET/CT,并将结果与计算的预检概率进行关联。

主要发现

  • 极低PSA值亚组中,紧凑模型平均预检阳性概率57%(95%CI 55-60%),综合模型59%(95%CI 56-61%)。
  • 低PSA值亚组中,紧凑模型平均预检阳性概率72%(95%CI 70-74%),综合模型74%(95%CI 72-76%)。
  • 图像分析后,极低PSA值亚组59%(89/151)的患者显示阳性影像发现。
  • 低PSA值亚组79%(112/141)的患者呈现68Ga-PSMA-11配体PET/CT阳性发现。
  • 预测模型准确度(AUC)紧凑模型为0.71(95%CI 0.65-0.78),综合模型为0.74(95%CI 0.68-0.80)。

关键数值与推荐

  • 极低PSA值亚组(0.2-0.5 ng/ml,n=151):紧凑模型平均预检概率57%(95%CI 55-60%),综合模型59%(95%CI 56-61%),实际阳性率59%(89/151)。
  • 低PSA值亚组(>0.5-1 ng/ml,n=141):紧凑模型平均预检概率72%(95%CI 70-74%),综合模型74%(95%CI 72-76%),实际阳性率79%(112/141)。
  • 预测模型AUC:紧凑模型0.71(95%CI 0.65-0.78),综合模型0.74(95%CI 0.68-0.80)。

临床怎么用

  • 原文结论未据此给出推荐。
  • 作者认为,鉴于医疗资源有限及混合影像技术成本,预测模型可能有助于患者选择。

局限性

  • 列线图本身的预测准确性欠佳,应谨慎使用。
  • 模型的外推性可能因研究设计(内部验证)而受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was the validation of a recently established comprehensive and compact prediction model for 68Ga-PSMA-11-ligand positron-emission tomography (PET) positivity with an independent subsequent patient series. METHODS: A total of 292 consecutive patients with early biochemical recurrence after radical prostatectomy and PSA values between 0.2 and 1 ng/ml who underwent 68Ga-PSMA-11-ligand PET/computed tomography (CT) between January 2016 and June 2017 were retrospectively included. The cohort was divided into a very low PSA value (0.2-0.5 ng/ml, n = 151) and a low PSA value (> 0.5-1 ng/ml, n = 141) subgroup. First, pre-test positivity probabilities for each patient were calculated according to the previously published comprehensive prediction model using all clinical variables (PSA value, ISUP grade group, T- and N-stage, patient under androgen deprivation therapy (ADT), previous radiation therapy) and the compact model using just the most predictive factors PSA value, ADT, and grade group. Then, all 68Ga-PSMA-11-ligand PET/CTs were analysed by one experienced nuclear medicine physician, and the results were correlated to the calculated pre-test probabilities. RESULTS: In the very low PSA value subgroup, mean pre-test probability for positive findings in 68Ga-PSMA-11-ligand PET/CT was 57% (95% CI 55-60%) according to the compact model and 59% (95% CI 56-61%) according to the comprehensive model. In the low PSA value subgroup, mean pre-test probability was 72% (95% CI 70-74%) in the compact model and 74% (95% CI 72-76%) in the comprehensive model. After image analysis, 59% (89/151) of the patients in the very low PSA value subgroup revealed positive imaging findings. Seventy-nine percent (112/141) of the patients in the low PSA value subgroup presented with positive findings in the 68Ga-PSMA-11-ligand PET/CT. The accuracy (AUC) of the prediction models was 0.71 (95% CI 0.65-0.78) for the compact model and 0.74 (95% CI 0.68-0.80) for the comprehensive model. CONCLUSION: External validation of the recently proposed prediction models showed a high concordance of the calculated pre-test probabilities and actual 68Ga-PSMA-11-ligand PET/CT findings in the validation cohort confirming the prediction models' ability to determine the presence of a positive lesion at 68Ga-PSMA-11-ligand PET. However, the predictive accuracy of the nomogram itself is suboptimal and should be used with caution. Furthermore, the model's generalizability may be hampered due to the study design (in-house validation). Nevertheless, given the limited health resources and the costs of hybrid imaging techniques, prediction models might be a benefit in patient selection.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Kraft P, Maurer T, Gafita A, et al. Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model. EJNMMI Res. 2020. PMID: 32016584. doi:10.1186/s13550-020-0595-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。